Cytogenetic, spectral karyotyping, fluorescence in situ hybridization, and comparative genomic hybridization characterization of two new secondary leukemia cell lines with 5q deletions, and MYC and MLL amplification

Genes Chromosomes and Cancer

Volumn 37, Issue 3, 2003, Pages 270-281

  Knutsen, Turid ^a   Pack, Svetlana ^b   Petropavlovskaja, Maria ^a,c   Padilla Nash, Hesed ^a   Knight, Clement ^a,d   Mickley, Lyn A ^a   Ried, Thomas ^a   Elwood, Patrick C ^a,e   Roberts, Susan J ^a,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d Maryland Oncology   (United States)

^e Licking Memorial Hospital   (United States)

^f NATIONAL RESEARCH COUNCIL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; PACLITAXEL; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME 1P; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME G BAND; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 8; COMPARATIVE GENOMIC HYBRIDIZATION; CSFIR GENE; CYTOGENETICS; DRUG INDUCED DISEASE; EGR1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE LOSS; GENE TRANSLOCATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IL3 GENE; IL4 GENE; IL5 GENE; IL9 GENE; IRF1 GENE; KARYOTYPING; LEUKEMIA CELL LINE; MALE; MLL GENE; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RBI GENE; SPECTRAL KARYOTYPING; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; ADULT; CHROMOSOME BANDING; CHROMOSOME PAINTING; CYTOGENETIC ANALYSIS; HODGKIN DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID; LEUKEMIA, RADIATION-INDUCED; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 0038207974     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10200     Document Type: Article

References (33)

1. Allen RJ, Smith SD, Moldwin RL, Lu M-M, Giordano L, Vignon C, Suto Y, Harden A, Tomek R, Veldman T, Ried T, Larson RA, Le Beau MM, Rowley JD, Zeleznik-Le N. 1998. Establishment and characterization of a megakaryoblast cell line with amplification of MLL. Leukemia 12:1119-1127.
2. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. 2001. Duplication of amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 31:33-41.
3. Boultwood J, Fidler C, Lewis S, MacCarthy A, Sheridan H, Kelly S, Oscier D, Buckle VJ, Wainscoat JS. 1993. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. Blood 82:2611-2616.
4. Carlson KM, Vignon C, Bohlander S, Martinez-Climent JA, Le Beau MM, Rowley JD. 2000. Identification and molecular characterization of CALM/AF10 fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia 14:100-104.
5. Castro PD, Liang JC, Nagarajan L. 2000. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 95:2138-2143.
6. Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J, Roberts IAG, Goldman JM, Cross NCP. 1999. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood 93:1025-1031.
7. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. 2001. Mutations with loss of heterozygosity of p53 are common in therapyrelated myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405-1413.
8. Coignet LJA, Lima CSP, Min T, Streubel B, Swansbury J, Telford N, Swanton S, Bowen A, Nagai M, Catovsky D, Fonatsch C, Dyer MJS. 1999. Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. Genes Chromosomes Cancer 25:222-229.
9. du Manoir S, Speicher MR, Joos S, Schröck E, Popp S, Döhner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T. 1993. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 90:590-610.
10. Felix CA, Winick NJ, Negrini M, Bowman WP, Croce CM, Lange BJ. 1993. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia. Cancer Res 53:2954-2956.
11. Felix CA, Megonigal MD, Chervinsky DS, Leonard DGB, Tsuchida N, Kakati S, Block AMW, Fisher J, Grossi M, Salhany KI, Jani-Sait N, Aplan PD. 1998. Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. Blood 91:4451-4456.
12. Green WB, Slovak ML, Chen I-M, Pallavicini M, Hecht JL, Willman CL. 1999. Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia 13:1960-1971.
13. Groupe Français de Cytogénétique Hématologique (GFCH). 1991. t(10;11)(p13-14;q14-21): a recurrent translocation in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 3:411-415.
14. Harrison CN, Vaughan Hudson G, Devereux S, Linch DC. 1998. Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience. Eur J Haematol 61:109-112.
15. Heim S, Mitelman F. 1995. Cancer cytogenetics, Second Ed. New York: Wiley-Liss.
16. Iurlo A, Mecucci C, Van Orshoven A, Michaux J-L, Boogaerts M, Noens L, Bosly A, Louwagie A, Van Den Berghe H. 1989. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 43:227-241.
17. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. 1991. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol 47:17-27.
18. Johansson B, Mertens F, Mitelman F. 1993. Cytogenetic deletion maps of hematological neoplasms: circumstantial evidence for tumor suppressor loci. Genes Chromosomes Cancer 8:205-218.
19. Kantarjian HM, Estey EH, Keating MJ. 1993. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 7:81-107.
20. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD. 1986. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4:325-345.
21. Le Beau MM, Espinosa R III, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA. 1993. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 90:5484-5488.
22. Levine EG, Bloomfield CD. 1992. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47-84.
23. Macville M, Veldman T, Padilla-Nash H, Wangsa D, O'Brien P, Schröck E, Ried T. 1997. Spectral karyotyping, a 24-colour FISH technique for the identification of chromosomal rearrangements. Histochem Cell Biol 108:299-305.
24. Merlar A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, Fenaux P. 1999. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 13:250-257.
25. Nagai M, Fujita M, Ikeda T, Ohmori M, Kuwabara H, Yamaoka G, Tanaka K, Kamada N, Taniwaki M, Inoue T, Irino S, Takahara J. 1997. Alterations of p53 and Rb genes in a novel human GMCSF-dependent myeloid cell line (OHN-GM) established from therapy-related leukaemia. Br J Haematol 98:392-398.
26. Nagarajan L. 1996. Deletion of chromosome 5 (5q-) in leukemia: current knowledge. In: Freireich EG, Kantarjian H, editors. Molecular genetics and therapy of leukemia. Boston: Kluwer Academic. p 19-29.
27. Nimer SD, Golde DW. 1987. The 5q- abnormality. Blood 70:1705-1712.
28. Rowley JD. 1993. Rearrangements involving chromosome band 11q23 in acute leukaemia. Cancer Biol 4:377-385.
29. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M, Kern W, Löffler H, Hiddemann W. 2002. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 35:20-29.
30. Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T. 1996. Multicolor spectral karyotyping of human chromosomes. Science 273:494-497.
31. Struebel B, Valent P, Jäger U, Edelhäuser M, Wandt H, Wagner T, Büchner T, Lechner K, Fonatsch C. 2000. Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes Chromosomes Cancer 27:380-386.
32. Super HJG, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO, Rowley JD. 1993. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82:3705-3711.
33. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF, Taniguchi T. 1993. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259:968-971.